110 related articles for article (PubMed ID: 23555966)
1. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus.
Sthoeger Z; Zinger H; Sharabi A; Asher I; Mozes E
PLoS One; 2013; 8(3):e60394. PubMed ID: 23555966
[TBL] [Abstract][Full Text] [Related]
2. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta.
Sharabi A; Zinger H; Zborowsky M; Sthoeger ZM; Mozes E
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8810-5. PubMed ID: 16735466
[TBL] [Abstract][Full Text] [Related]
3. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis.
Ben-David H; Sharabi A; Parameswaran R; Zinger H; Mozes E
Immunology; 2009 Oct; 128(2):245-52. PubMed ID: 19740381
[TBL] [Abstract][Full Text] [Related]
4. Identification of IFI44L as a new candidate molecular marker for systemic lupus erythematosus.
Wang Y; Jia W; Ma Q; Li F; Ma Z; Yang M; Pu J; Huo Z; Dang J
Clin Exp Rheumatol; 2023 Jan; 41(1):48-59. PubMed ID: 35349411
[TBL] [Abstract][Full Text] [Related]
5. Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets.
Bradford HF; Haljasmägi L; Menon M; McDonnell TCR; Särekannu K; Vanker M; Peterson P; Wincup C; Abida R; Gonzalez RF; Bondet V; Duffy D; Isenberg DA; Kisand K; Mauri C
Cell Rep Med; 2023 Jan; 4(1):100894. PubMed ID: 36652906
[TBL] [Abstract][Full Text] [Related]
6. Identification of Peptides as Novel Inhibitors to Target IFN-
Mustafa G; Mahrosh HS; Salman M; Sharif S; Jabeen R; Majeed T; Tahir H
Biomed Res Int; 2021; 2021():1124055. PubMed ID: 34812407
[TBL] [Abstract][Full Text] [Related]
7. Unraveling transcriptomic signatures and dysregulated pathways in systemic lupus erythematosus across disease states.
Wang FQ; Shao L; Dang X; Wang YF; Chen S; Liu Z; Mao Y; Jiang Y; Hou F; Guo X; Li J; Zhang L; Sang Y; Zhao X; Ma R; Zhang K; Zhang Y; Yang J; Wen X; Liu J; Wei W; Zhang C; Li W; Qin X; Lei Y; Feng H; Yang X; She CH; Zhang C; Su H; Chen X; Yang J; Lau YL; Wu Q; Ban B; Song Q; Yang W
Arthritis Res Ther; 2024 May; 26(1):99. PubMed ID: 38741185
[TBL] [Abstract][Full Text] [Related]
8. Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes.
Zhang Z; Song L; Maurer K; Petri MA; Sullivan KE
Genes Immun; 2010 Mar; 11(2):124-33. PubMed ID: 19710693
[TBL] [Abstract][Full Text] [Related]
9. Interferon-λs: special immunomodulatory agents and potential therapeutic targets.
Zheng YW; Li H; Yu JP; Zhao H; Wang SE; Ren XB
J Innate Immun; 2013; 5(3):209-18. PubMed ID: 23207147
[TBL] [Abstract][Full Text] [Related]
10. S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases.
Duguet F; Ortega-Ferreira C; Fould B; Darville H; Berger S; Chomel A; Leclerc G; Kisand K; Haljasmägi L; Hayday AC; Desvaux E; Nony E; Moingeon P; De Ceuninck F
J Transl Autoimmun; 2021; 4():100093. PubMed ID: 33748735
[TBL] [Abstract][Full Text] [Related]
11. Single-cell RNA-sequencing of peripheral blood mononuclear cells reveals widespread, context-specific gene expression regulation upon pathogenic exposure.
Oelen R; de Vries DH; Brugge H; Gordon MG; Vochteloo M; ; ; Ye CJ; Westra HJ; Franke L; van der Wijst MGP
Nat Commun; 2022 Jun; 13(1):3267. PubMed ID: 35672358
[TBL] [Abstract][Full Text] [Related]
12. Limited effectiveness for the therapeutic blockade of interferon α in systemic lupus erythematosus: a possible role for type III interferons.
Amezcua-Guerra LM; Ferrusquía-Toriz D; Castillo-Martínez D; Márquez-Velasco R; Chávez-Rueda AK; Bojalil R
Rheumatology (Oxford); 2015 Feb; 54(2):203-5. PubMed ID: 24625504
[No Abstract] [Full Text] [Related]
13. The crucial regulatory role of type I interferon in inflammatory diseases.
Ji L; Li T; Chen H; Yang Y; Lu E; Liu J; Qiao W; Chen H
Cell Biosci; 2023 Dec; 13(1):230. PubMed ID: 38124132
[TBL] [Abstract][Full Text] [Related]
14. A Multicenter Cohort Study of Immune Dysregulation Disorders Caused by ELF4 Variants in China.
Sun G; Wu M; Lv Q; Yang X; Wu J; Tang W; Dai R; Zhou L; Ding Y; Zhang Z; An Y; Tang X; Zheng X; Wang Z; Sun L; Xie Y; Zhao X; Du H
J Clin Immunol; 2023 Jul; 43(5):933-939. PubMed ID: 36823308
[TBL] [Abstract][Full Text] [Related]
15. Retracted: Identification of Peptides as Novel Inhibitors to Target IFN-
International BR
Biomed Res Int; 2024; 2024():9756587. PubMed ID: 38550163
[TBL] [Abstract][Full Text] [Related]
16. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.
ACCESS Trial Group
Arthritis Rheumatol; 2014 Nov; 66(11):3096-104. PubMed ID: 25403681
[TBL] [Abstract][Full Text] [Related]
17. Naringin-Dextrin Nanocomposite Abates Diethylnitrosamine/Acetylaminofluorene-Induced Lung Carcinogenesis by Modulating Oxidative Stress, Inflammation, Apoptosis, and Cell Proliferation.
Mohamed EE; Ahmed OM; Zoheir KMA; El-Shahawy AAG; Tamur S; Shams A; Burcher JT; Bishayee A; Abdel-Moneim A
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894468
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory and anti-oxidant activities of mesenchymal stem cells in chemically induced arthritic rats.
Zaky MY; Mohamed EE; Mahmoud R; Halfaya FM; Farghali A; Abo El-Ela FI
Mol Biol Rep; 2023 Dec; 50(12):9951-9961. PubMed ID: 37878206
[TBL] [Abstract][Full Text] [Related]
19. Peptide-based immunotherapy in lupus: Where are we now?
P Singh R; S Bischoff D; S Singh S; H Hahn B
Rheumatol Immunol Res; 2023 Sep; 4(3):139-149. PubMed ID: 37781681
[TBL] [Abstract][Full Text] [Related]
20. A Novel Hydroxyapatite/Vitamin B
Belal A; Mahmoud R; Mohamed EE; Farghali A; Abo El-Ela FI; Gamal A; Halfaya FM; Khaled E; Farahat AA; Hassan AHE; Ghoneim MM; Taha M; Zaky MY
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
